Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

Simple item page
dc.contributor.authorSikander Ailawadhi
dc.contributor.authorSwetha Challagulla
dc.contributor.authorPo-Ya Chuang
dc.contributor.authorWesley Furnback
dc.contributor.authorKeri Yang
dc.coverage.spatialBolivia
dc.date.accessioned2026-03-22T20:02:44Z
dc.date.available2026-03-22T20:02:44Z
dc.date.issued2026
dc.description.abstractThis real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU than acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.
dc.identifier.doi10.1080/17474086.2026.2628534
dc.identifier.urihttps://doi.org/10.1080/17474086.2026.2628534
dc.identifier.urihttps://andeanlibrary.org/handle/123456789/79658
dc.language.isoen
dc.publisherTaylor & Francis
dc.relation.ispartofExpert Review of Hematology
dc.sourceWinnMed
dc.subjectMedicine
dc.subjectIbrutinib
dc.subjectDiscontinuation
dc.subjectChronic lymphocytic leukemia
dc.subjectBruton's tyrosine kinase
dc.subjectOncology
dc.subjectInternal medicine
dc.subjectTyrosine kinase
dc.subjectHealth care
dc.subjectLeukemia
dc.titleReal-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia
dc.typearticle

Files

Collections

Artículo Científico Publicado